The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A Multicenter, Randomized, Double-Blind, Crossover Study to Evaluate Patient Preference between Tadalafil and Sildenafil
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another randomized, double-blind, crossover study comparing tadalafil with sildenafil reported that 132 of 181 (73%) chose to receive tadalafil during the extension phase of the trial, irrespective of previous sildenafil use (p < 0.001) (von Keitz et al 2004).”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as von Keitz et al 2004
In the citing paper
“Prospective, randomized studies including over 750 men with various severities and etiologies of ED have found a preference for tadalafil over sildenafil by significant margins (Eardley et al 2005; Govier et al 2003; von Keitz et al 2004).”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as von Keitz et al 2004
In the citing paper
“Men with diabetes had an 87% preference for tadalafil over sildenail (p < 0.001), and men with hypertension had a 79% preference for tadalafil (p < 0.001) (von Keitz et al 2004).”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as von Keitz et al 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oral Sildenafil in the Treatment of Erectile Dysfunction
Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., & Wicker, P. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382001 · Cited by 2,120
Research works printed but not linked: 24
- Stiggelbout, 2001, Patient preference for cancer therapy: an overview of measurement approaches, J. Clin. Oncol., 19, 220, 10.1200/JCO.2001.19.1.220 · DOI
- McKinlay, 2000, The worldwide prevalence and epidemiology of erectile dysfunction, Int. J. Impot. Res., 12, S6, 10.1038/sj.ijir.3900567 · DOI · Paper page
- Fugl-Meyer, 1997, On life satisfaction in male erectile dysfunction, Int. J. Impot. Res., 9, 141, 10.1038/sj.ijir.3900269 · DOI · Paper page
- NIH Consensus Development Panel on Impotence. Impotence. JAMA 1993;270:83–90. · DOI
- Leiblum, 2002, After sildenafil: bridging the gap between pharmacologic treatment and satisfying sexual relationships, J. Clin. Psychiatry, 63, 17
- Porst, 2002, IC351 (tadalafil, Cialis): update on clinical experience, Int. J. Impot. Res., 14, S57, 10.1038/sj.ijir.3900807 · DOI
- Chen, 2001, Sildenafil versus the vacuum erection device: patient preference, J. Urol., 166, 1779, 10.1016/S0022-5347(05)65674-1 · DOI
- Hatzichristou, 2000, Sildenafil versus intracavernous injection therapy: efficacy and preference in patients on intracavernous injection for more than 1 year, J. Urol., 164, 1197, 10.1016/S0022-5347(05)67140-6 · DOI
- Seftel, 2002, Challenges in oral therapy for erectile dysfunction, J. Androl., 23, 729, 10.1002/j.1939-4640.2002.tb02323.x · DOI
- Brock, 2002, Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses, J. Urol., 168, 1332, 10.1016/S0022-5347(05)64442-4 · DOI · Paper page
- Padma-Nathan, 2001, Cialis™ (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction (ED) [abstract], J Urol, S165, 224
- Porst, 2003, Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36hours after dosing: A randomized controlled trial, Urology, 62, 121, 10.1016/S0090-4295(03)00359-5 · DOI · Paper page
- Seftel, 2003, Efficacy and safety of tadalafil in US men with ED [abstract], J Urol, S169, 376
- Rosen, 1997, The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction, Urology, 49, 822, 10.1016/S0090-4295(97)00238-0 · DOI · Paper page
- El Galley, 2001, Long-term efficacy of sildenafil and tachyphylaxis effect, J. Urol., 166, 927, 10.1016/S0022-5347(05)65866-1 · DOI
- Marks, 1999, Treatment of erectile dysfunction with sildenafil, Urology, 53, 19, 10.1016/S0090-4295(98)00525-1 · DOI
- Orrico, 1998, Sildenafil Dose Titration Program, Am. J. Health Syst. Pharm., 55, 2297
- Fink, 2002, Sildenafil for Male Erectile Dysfunction: a systematic review and meta-analysis, Arch. Intern. Med., 162, 1349, 10.1001/archinte.162.12.1349 · DOI
- Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H on behalf of the Vardenafil Study Group. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002;23:763–71. · DOI · Paper page
- Padma-Nathan H, McMurray JG, Pullman WE, Whitaker JS, Saoud JB, Ferguson KM, Rosen RC for the IC351 On-Demand Dosing Study Group. On-demand IC351 (Cialis TM) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001;13:2–9. · DOI
- Boulton, 2001, Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus, Diabetologia, 44, 1296, 10.1007/s001250100656 · DOI
- Guay, 2001, Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors, J. Androl., 22, 793, 10.1002/j.1939-4640.2001.tb02582.x · DOI · Paper page
- McMahon, 2000, Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction, J. Urol., 164, 1192, 10.1016/S0022-5347(05)67139-X · DOI
- Virag, 1999, Indications and early results of sildenafil (Viagra) in erectile dysfunction, Urology, 54, 1073, 10.1016/S0090-4295(99)00310-6 · DOI
Cited by
Tadalafil in the treatment of erectile dysfunction
Coward, R., & Carson, C. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3336 · Cited by 138
Corona, G., Rastrelli, G., Burri, A., Jannini, E. A., & Maggi, M. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1130126 · Cited by 71
Metadata
- Authors
- von Keitz, A., Rajfer, J., Segal, S., Murphy, A., Denne, J., Costigan, T., Lockhart, D., Beasley, C. M., & Emmick, J. T.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2004-04
- Volume
- 45
- Issue
- 4
- Pages
- 499-509
- ISSN
- 0302-2838
- Cited by
- 82
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
